New Delhi, Jun 30 (PTI) Zydus Cadila today said it has received USFDA approval to market Triamterene and Hydrochlorothiazide tablets, indicated to treat high blood pressure. Also Read - 4 More Coronavirus Vaccines Other Than Covishield, Covaxin Coming Soon, Says Health Ministry
The approval has been granted for the tablets in strengths of 37.5 mg/25 mg and 75 mg/50 mg. Also Read - Govt Actively Working to Support COVID-19 Vaccine Manufacturers: PM Modi After Visiting Zydus Cadila
“The combination drug is used for the treatment of high blood pressure. It is is used by patients who have developed or are at risk for having low potassium levels on hydrochlorothiazide,” Zydus said in a BSE filing. Also Read - 6 Indian Companies Start Working on Vaccine for COVID-19, But It Won't be Ready Until 2021
The drug will be manufactured at the group’s manufacturing facility at SEZ, Ahmedabad.
The group now has more than 195 approvals and has so far filed over 320 ANDAs since the commencement of the filing process in 2003-04.
Zydus Cadila discovers, develops, manufactures and markets a broad range of healthcare therapies.
This is published unedited from the PTI feed.